BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LN-145 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LN-145\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03449108-2048@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LN-145: Phase 2 readout est. (NCT03449108)
DESCRIPTION:LN-145\, phase 2.\nStudy: LN-145 or LN-145-S1 in Treating Patie
 nts With Relapsed or Refractory Ovarian Cancer\, Triple Negative Breast Ca
 ncer (TNBC)\, Anaplastic Thyroid Cancer\, Osteosarcoma\, or Other Bone and
  Soft Tissue Sarcomas\nEstimated primary completion: 30 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ln-145#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03449108
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05607095-2048@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:LN-145: Phase 1 readout est. (NCT05607095)
DESCRIPTION:LN-145\, phase 1.\nStudy: A Study of LN-144 or LN-145 in People
  With Advanced Uveal Melanoma\, Undifferentiated Pleomorphic Sarcoma\, Ded
 ifferentiated Liposarcoma\, or Angiosarcoma\nEstimated primary completion:
  1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ln-145#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05607
 095
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288073-2048@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:LN-145: Phase 2 readout est. (NCT07288073)
DESCRIPTION:LN-145\, phase 2.\nStudy: TIL Therapy in cSCC and MCC\nEstimate
 d primary completion: 29 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ln-145#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07288073
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614103-2048@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:LN-145: Phase 2 readout est. (NCT04614103)
DESCRIPTION:LN-145\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Autologo
 us LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer\nEstimate
 d primary completion: December 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ln-145#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04614103
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
